Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
CLDX
SellHot AirCelldex Therapeutics, Inc. · Healthcare · United States · $3.1B · Avg Vol: $31M/d
COMPANY DESCRIPTION
Celldex Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutic monoclonal antibodies for inflammatory, autoimmune, and oncology indications. The company's competitive moat is centered on its proprietary pipeline, particularly barzolvolimab, a clinical-stage candidate targeting mast cell-driven diseases like chronic urticaria. It operates as a high-potential biotechnology innovator with a robust intellectual property portfolio in immunology.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.4M | 6.9M | 7.0M | 1.5M | -13.1% | — | 2.0M | — | 31.5% |
| EPS | -2.40 | -2.92 | -2.45 | -3.90 | — | -4.35 | -4.12 | -4.21 | — |
| Shares | 47.2M | 55.9M | 66.4M | 66.5M | +41.0% | 78.5M | — | — | — |
| Debt | 4.0M | 2.5M | 3.8M | 2.3M | -16.6% | 4.9M | — | — | — |
| Equity | 326.2M | 429.2M | 747.0M | 527.2M | 17.4% | — | — | — | — |
| Op CF | -103.7M | -107.3M | -157.8M | -210.9M | — | -235.6M | — | — | — |
| Inv CF | 89.9M | -105.8M | -290.1M | 209.1M | — | — | — | — | — |
| Fin CF | 4.1M | 218.5M | 441.4M | 2.4M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of CLDX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| CLDX | Celldex Therapeutics, Inc.(you) | $3.1B | 25 | Sell |
| MRVI | Maravai LifeSciences Holdings, Inc. | $2.8B | 24 | Sell |
| MBX | MBX Biosciences, Inc. | $3.0B | 28 | Sell |
| IRON | Disc Medicine, Inc. | $3.1B | 22 | Sell |
| ATAI | AtaiBeckley Inc. | $2.7B | 23 | Sell |
| NRIX | Nurix Therapeutics, Inc. | $2.7B | 28 | Sell |
| IMNM | Immunome, Inc. | $3.1B | 20 | Strong Sell |
| NKTR | Nektar Therapeutics | $2.5B | 23 | Sell |
| PGEN | Precigen, Inc. | $2.5B | 28 | Sell |
| TRVI | Trevi Therapeutics, Inc. | $2.4B | 28 | Sell |
Peer medians: ROE -30.5% · P/E 27.0x · Gross margin 58.3%